While monotherapy with IDO1 inhibition has not demonstrated robust clinical activity [63], promising results have been demonstrated with the combination of the IDO1 inhibitor epacadostat (INCB024360) and ipilimumab in patients with advanced melanoma. Here, IDO1 is linked to melanoma.